9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym]
dextroamphetamine
RxCUI: 2624735
What the CMS Formulary Data Shows for 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym]
Per the CMS 2026 Part D formulary file, 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] (RxNorm concept RXCUI 2624735, generic name dextroamphetamine) appears on 1 distinct formulary file spanning 1 Medicare Part D plan offering - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 2, with a cross-plan average of Tier 2.
Real-world access to 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 47 Part D beneficiaries filled 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] in 2023, with total plan-and-beneficiary spending of $51,043 and an average per-beneficiary annual cost of $1,086.02. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 1
- Coverage rate
- 0%
- Tier range
- Tier 2, Generic
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 47
- Total spending
- $51,043
- Avg per beneficiary
- $1,086.02
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym]
1 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CareAdvantage (HMO D-SNP) | SAN MATEO HEALTH COMMISSION | T2 | No | $0 | CA |
Frequently Asked Questions
Is 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] covered by Medicare Part D?
Yes, 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] is covered by 1 Medicare Part D plans (0% of all Part D formularies).
What tier is 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] on Medicare Part D plans?
9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] averages Tier 2 across Part D plans, ranging from Tier 2 to Tier 2.
Does 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] require prior authorization?
0% of Part D formularies require prior authorization for 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym]?
In 2023, total Medicare Part D spending on 9 HR dextroamphetamine 1 MG/HR Transdermal System [Xelstrym] was $51,043, covering 47 beneficiaries. The average spend per beneficiary was $1,086.02.
Read our methodology - how this data is sourced, computed, and verified.